395 related articles for article (PubMed ID: 27771166)
21. Clinicopathological analysis of mullerian adenosarcoma of the uterus.
Han XY; Xiang Y; Guo LN; Shen K; Wan XR; Huang HF; Pan LY
Chin Med J (Engl); 2010 Mar; 123(6):756-9. PubMed ID: 20368100
[No Abstract] [Full Text] [Related]
22. Survival After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A National Cancer Database Study.
Seagle BL; Graves S; Strohl AE; Shahabi S
Int J Gynecol Cancer; 2017 Oct; 27(8):1610-1618. PubMed ID: 28763362
[TBL] [Abstract][Full Text] [Related]
23. Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome.
Callister M; Ramondetta LM; Jhingran A; Burke TW; Eifel PJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):786-96. PubMed ID: 14967435
[TBL] [Abstract][Full Text] [Related]
24. Uterine adenosarcomas: a dual-institution update on staging, prognosis and survival.
Bernard B; Clarke BA; Malowany JI; McAlpine J; Lee CH; Atenafu EG; Ferguson S; Mackay H
Gynecol Oncol; 2013 Dec; 131(3):634-9. PubMed ID: 24135678
[TBL] [Abstract][Full Text] [Related]
25. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
[TBL] [Abstract][Full Text] [Related]
26. [Mullerian adenosarcoma of the uterus: A clinicopathologic analysis of 9 cases].
Han XY; Xiang Y; Guo LN; Sheng K; Wan XR; Huang HF; Pan LY
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):44-7. PubMed ID: 20211067
[TBL] [Abstract][Full Text] [Related]
27. Survival Analysis of Cancer Patients With FIGO Stage IIIA Endometrial Cancer.
Lum MM; Belnap TW; Frandsen J; Brown AP; Sause WT; Soisson AP; Dodson MK; Werner T; Gaffney DK
Am J Clin Oncol; 2015 Jun; 38(3):283-8. PubMed ID: 23774072
[TBL] [Abstract][Full Text] [Related]
28. Postoperative Chemoradiation Therapy in High-Risk Cervical Cancer: Re-evaluating the Findings of Gynecologic Oncology Group Study 109 in a Large, Population-Based Cohort.
Trifiletti DM; Swisher-McClure S; Showalter TN; Hegarty SE; Grover S
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1032-44. PubMed ID: 26581141
[TBL] [Abstract][Full Text] [Related]
29. FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973-87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina.
Kosary CL
Semin Surg Oncol; 1994; 10(1):31-46. PubMed ID: 8115784
[TBL] [Abstract][Full Text] [Related]
30. Mullerian adenosarcoma of the female genital tract.
McCluggage WG
Adv Anat Pathol; 2010 Mar; 17(2):122-9. PubMed ID: 20179434
[TBL] [Abstract][Full Text] [Related]
31. Association between developmental steps in the organogenesis of the uterine cervix and locoregional progression of cervical cancer: a prospective clinicopathological analysis.
Höckel M; Hentschel B; Horn LC
Lancet Oncol; 2014 Apr; 15(4):445-56. PubMed ID: 24656439
[TBL] [Abstract][Full Text] [Related]
32. Uterine adenosarcoma with ovarian sex cord-like differentiation: a case report and review of the literature.
Ulker V; Yavuz E; Gedikbasi A; Numanoglu C; Sudolmus S; Gulkilik A
Taiwan J Obstet Gynecol; 2011 Dec; 50(4):518-21. PubMed ID: 22212329
[TBL] [Abstract][Full Text] [Related]
33. Uterine Adenosarcoma.
Ulrich UA; Denschlag D
Oncol Res Treat; 2018; 41(11):693-696. PubMed ID: 30326467
[TBL] [Abstract][Full Text] [Related]
34. [Prognosis-related clinicopathologic characteristics of FIGO stage Ⅰ Müllerian adenosarcoma of uterus].
Wang Y; Liu AJ; Chen X; Song X
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):334-338. PubMed ID: 29783798
[No Abstract] [Full Text] [Related]
35. Epidemiology of adenosarcoma and the inverse probability of treatment weighting (IPTW) adjusted survival analysis of lymph node dissection in uterine adenosarcoma.
Hu H; Wei Z; Zhao H; Yuan G
Medicine (Baltimore); 2022 Sep; 101(38):e30607. PubMed ID: 36197202
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic features, incidence, and survival trends of gynecologic neuroendocrine tumors: a SEER database analysis.
Gibbs J; Mei S; Economos K; Lee YC; Kanis MJ
Am J Obstet Gynecol; 2019 Jul; 221(1):53.e1-53.e6. PubMed ID: 30849352
[TBL] [Abstract][Full Text] [Related]
37. Higher positive lymph node ratio indicates poorer distant metastasis-free survival in adenoid cystic carcinoma patients with nodal involvement.
Liu Z; Fang Z; Dai T; Zhang C; Sun J; He Y
J Craniomaxillofac Surg; 2015 Jul; 43(6):751-7. PubMed ID: 25958766
[TBL] [Abstract][Full Text] [Related]
38. Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: most common locations and outcomes.
Gardner AB; Charo LM; Mann AK; Kapp DS; Eskander RN; Chan JK
Clin Exp Metastasis; 2020 Feb; 37(1):107-113. PubMed ID: 31758289
[TBL] [Abstract][Full Text] [Related]
39. [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
Ma SK; Zhang HT; Sun YC; Wu LY
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):690-4. PubMed ID: 19173912
[TBL] [Abstract][Full Text] [Related]
40. Safety of ovarian preservation in women with stage I and II cervical adenocarcinoma: a retrospective study and meta-analysis.
Chen J; Wang R; Zhang B; Lin X; Wei J; Jia Y; Yin Y; Ye S; Zhu T; Chen G; Yuan Y; Lu W; Li K
Am J Obstet Gynecol; 2016 Oct; 215(4):460.e1-460.e13. PubMed ID: 27133009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
